T-cell immunomodulation

T-cell immunomodulation refers to the therapeutic manipulation of T-lymphocyte activity to either enhance or suppress immune responses depending on the clinical need. In oncology, this strategy primarily involves the use of immune checkpoint inhibitors, such as those targeting PD-1 or CTLA-4, to restore the ability of cytotoxic T-cells to recognize and eliminate tumor cells (Nature Reviews Drug Discovery, 2018). In contrast, for autoimmune diseases and organ transplantation, immunomodulation aims to induce tolerance or suppress T-cell activation through agents like calcineurin inhibitors or costimulation blockers (Journal of Clinical Investigation, 2015). The process involves a complex interplay of signals from the T-cell receptor (TCR) and various co-receptors that determine the magnitude and duration of the immune response (Frontiers in Immunology, 2020). These signals are critical for maintaining self-tolerance while allowing for robust responses against pathogens and malignancies. While these therapies have revolutionized the treatment of many diseases, they are associated with significant risks, including immune-related adverse events (irAEs) and cytokine release syndrome (The Lancet, 2021). These side effects result from the systemic loss of immune control or excessive cytokine production. Overall, T-cell immunomodulation represents a cornerstone of modern precision medicine and immunotherapy.

Other names

T-cell modulationImmune modulationT-cell regulationT-cell immunotherapy

T-cell immunomodulation involves the use of therapeutic agents to either stimulate T-cell activity (e.g., via checkpoint inhibition) or suppress it (e.g., via calcineurin inhibition or costimulation blockade) to treat cancer, autoimmune diseases, or transplant rejection (Nature Reviews Drug Discovery, 2018).